UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Understand the advantages of choosing no fee high cash back credit cards. Make a financially savvy choice for your wallet.
27,451 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
As tariffs re-emerge under Section 301, policymakers push a framework that has endured decades of legal challenges. T...
Two leading prediction-market platforms are pursuing high-value fundraising as U.S. lawmakers eye tighter rules. Iran...
AI and crypto funders dumped millions into Illinois Democratic primaries, yet the results show money did not move the...
Target's Circle Deal Days is more than a promo. It could be a lever for traffic, online sales, and margins. This arti...
MISMO and ALTA unveiled two datasets in candidate recommendation status to digitize ALTA title and settlement data, s...
AMD delivered a strong Q1 FY2026, prompting a broad uprising in analyst targets. Nine firms boosted price targets as ...
DeFi endured its worst April in over a year, with hundreds of millions lost to hacks. The sector now faces a shift to...
Open Society Foundations committing $30 million over three years to support interfaith partnerships and protect commu...
The 2025 GFLEC index shows no improvement in Americans’ financial literacy since 2017, with gaps by gender and race w...
A standout move in the world of investing: a wealth manager makes a sizable bet on an active international rotation E...
Regulators are leaning into nonprofit oversight, boosting enforcement actions even as verified cases of nonprofit fra...